Glaukos Completes Acquisition of Avedro, Inc.
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has completed its previously announced acquisition of Avedro, Inc. (Nasdaq: AVDR). “Today marks an important day for Glaukos as Avedro will serve as the cornerstone of our new corneal health franchise,” said Thomas Burns, Glaukos president and